WHO Drug Information articles from June 2001

WHO Drug Information archives from June 2001

Internet pharmacies: advantages and risks. (Personal Perspectives).
June 22, 2001... Harri Ovaskainen Director for Pharmaceutical Affairs Finnish Pharmacists Association Helsinki, Finland The Internet, first developed as a resource to facilitate communication, has now grown into a global network of computer...

Atypical antipsychotics and impaired glucose metabolism. (Reports on Individual Drugs).
June 22, 2001... Jenna Griffiths and Pascale Springuel, Bureau of Licensed Product Assessment, Therapeutic Products Directorate, Health Canada (*) The new atypical antispychotics clozapine, olanzapine, quetiapine and risperidone are among first-line...

Antituberculosis drugs: hepatobiliary reactions. (Reports on Individual Drugs).
June 22, 2001... Duc Vu and Lynn Macdonald, Bureau of Licensed Product Assessment, Therapeutic Products Directorate, Health Canada According to the latest edition of the Canadian Tuberculosis Standards (1) Canada has one of the lowest reported incidence...

WHO pilot pre-qualification project for pharmaceutical products. (Quality Assurance Issues).
June 22, 2001... It is recognized that low-cost drugs of assured quality have the greatest potential for maximizing efforts to combat major communicable diseases. As an integral part of their health care programmes and services, WHO and many other international...

Antimicrobials in animal feed: a threat to human use. (Current Topics).
June 22, 2001... Antimicrobials have been used in food animals in North America and Europe for nearly half a century. Among the most common are drugs that are either identical to or related to those administered to humans, including penicillins, tetracyclines,...

Declaration of Helsinki and placebo-controlled clinical trials. (Current Topics).
June 22, 2001... The Declaration of Helskinki is acknowledged as the cornerstone of research ethics. Its current guidelines on the ethical use of placebo-controlled trials has caused some confusion in the research world and for this reason the Council of the...

Improving the quality and usefulness of drug regulatory authority websites. (General Information).
June 22, 2001... The internet can be a valuable resource for users seeking health information. For most patients, health professionals, policy makers and pharmaceutical companies, the website of the national drug regulatory authority should be the most...

Regulatory and safety matters (*).
June 22, 2001... Infliximab and congestive heart failure United States of America -- The manufacturer of infliximab (Remicade[R]) has issued a warning concerning new safety information. Infliximab is a biological therapeutic product indicated for the...

ATC/DDD classification (final).
June 22, 2001... ATC/DDD Classification (final) The following final anatomical therapeutic chemical (ATC) classifications and defined daily doses (DDDs) were agreed at a meeting of the WHO International Working Group for Drug Statistics Methodology...

ATC/DDD classification (temporary).
June 22, 2001... ATC/DDD Classification (temporary) The following temporary anatomical therapeutic chemical (ATC) classifications and defined daily doses (DDDs) were agreed at a meeting of the WHO International Working Group for Drug Statistics...

Internet purchase of pharmaceuticals: a review of regulatory experience (*). (Regulatory Information).
June 22, 2001... Countries vary considerably with regard to regulation of medicines sold over the Internet. Because of the cross-border nature of the Internet, regulations at international level should be favoured whenever possible particularly if these are...

International Nonproprietary Names for Pharmaceutical Substances (INN).
June 22, 2001... RECOMMENDED International Nonproprietary Names (Rec. INN): List 46 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical...